EMEA-001175-PIP01-11-M04

Key facts

Invented name
Eperzan
Active substance
Albiglutide
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0272/2016
PIP number
EMEA-001175-PIP01-11-M04
Pharmaceutical form(s)
Powder and solvent for solution for injection
Condition(s) / indication(s)
Treatment of type II diabetes mellitus
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Glaxo Group Limited

Tel. +44 (0)20 8990 3650
E-mail: eu.paediatric-plans@gsk.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating